Global Journal of Research in
Biology and Pharmacy
Journal homepage: https://gsjournals.com/gjrbp/
ISSN: 2980-4221 (Online)

(REVIEW ARTICLE)

Check for updates

HUMAN MICROBIOME AND LIVE BIOTHERAPEUTIC PRODUCTS: REGULATORY ADVANCES AND CLINICAL APPLICATIONS

Shreya Sudhir Palanivel *

B. Pharmacy Student, India.
* Corresponding Author

Global Journal of Research in Biology and Pharmacy, 2024, 03(01), 001–005

Publication history: Received on 04 January 2024; revised on 24 January 2024; accepted on 29 January 2024

Article DOI: https://doi.org/10.58175/gjrbp.2024.3.1.0010

ABSTRACT

The human microbiome, comprising trillions of microorganisms residing primarily in the gastrointestinal tract, plays a fundamental role in host metabolism, immunity, and disease pathogenesis. Dysbiosis—an imbalance in microbial community structure and function—has been associated with a wide range of conditions, including Clostridioides difficile infection, inflammatory bowel disease, metabolic disorders, and even oncologic and neurologic diseases. Live biotherapeutic products, defined as biological products containing live microorganisms intended for prevention, treatment, or cure of a disease, represent a novel therapeutic class distinct from conventional probiotics. This review examines the evolving regulatory landscape for live biotherapeutic products, focusing on frameworks developed by the US Food and Drug Administration and the European Medicines Agency, and discusses key clinical applications and evidence through 2023. The most advanced live biotherapeutic products are those targeting recurrent Clostridioides difficile infection, with several candidates demonstrating efficacy in reducing recurrence. Other areas, including ulcerative colitis, atopic dermatitis, and immuno-oncology, are being explored, although evidence is less mature. Critical challenges include manufacturing standardization, strain characterization, engraftment and colonization dynamics, safety in immunocompromised populations, and the need for well-designed clinical trials. Future directions include defined consortia, engineered microbes, and microbiome-based diagnostics for patient stratification. Overall, live biotherapeutic products hold significant promise, but rigorous regulatory and scientific standards are essential to translate microbiome science into clinical benefit.

Keywords: Human Microbiome; Live Biotherapeutic Product; Clostridioides Difficile; Dysbiosis; Regulatory Framework; Fecal Microbiota Transplantation

1 INTRODUCTION

The human body harbors a vast and diverse microbial ecosystem, collectively termed the microbiome. The gastrointestinal tract alone contains an estimated 10^{13} to 10^{14} microorganisms, including bacteria, archaea, viruses, and fungi, whose collective genomes vastly outnumber the human genome. Advances in high-throughput sequencing and bioinformatics have revealed that the microbiome is not merely a passive collection of commensals but an active participant in host physiology. It contributes to nutrient metabolism, synthesis of vitamins and short-chain fatty acids, maturation of the immune system, and protection against pathogens. Disruption of this ecosystem—dysbiosis—has

been implicated in a growing list of diseases, from gastrointestinal disorders to metabolic syndrome, cardiovascular disease, autoimmune conditions, and even neurological disorders.

The recognition of the microbiome's role in health and disease has led to therapeutic strategies aimed at restoring a healthy microbial community. Fecal microbiota transplantation, the transfer of stool from a healthy donor to a patient, has been used for recurrent Clostridioides difficile infection with high efficacy. However, fecal microbiota transplantation is associated with challenges related to standardization, safety, and donor screening. In response, live biotherapeutic products have emerged as a more defined and regulated approach. According to the US Food and Drug Administration, a live biotherapeutic product is a biological product that contains live organisms, such as bacteria, and is applicable to the prevention, treatment, or cure of a disease or condition in human beings. This definition distinguishes live biotherapeutic products from conventional probiotics, which are generally intended for maintenance of health in healthy individuals and are regulated as dietary supplements or foods.

This review critically examines the regulatory advances governing live biotherapeutic products and their clinical applications, with a focus on evidence published through 2023. It covers the scientific rationale, key regulatory frameworks, major clinical trials, challenges, and future directions.

2 THE HUMAN MICROBIOME: COMPOSITION, FUNCTION, AND DYSBIOSIS

2.1 Composition and Dynamics

The human gut microbiome is dominated by two bacterial phyla, Firmicutes and Bacteroidetes, with smaller contributions from Actinobacteria, Proteobacteria, and Verrucomicrobia. Composition varies along the gastrointestinal tract, with the colon harboring the highest density. The microbiome is dynamic, influenced by diet, age, genetics, medications, and environment. Early-life colonization shapes immune development, and perturbations during critical windows can have lasting consequences.

2.2 Metabolic and Immunological Functions

Gut microbes ferment indigestible carbohydrates into short-chain fatty acids such as acetate, propionate, and butyrate, which serve as energy sources for colonocytes and modulate host metabolism. Butyrate, in particular, has anti-inflammatory properties and supports intestinal barrier integrity. The microbiome also synthesizes vitamins (e.g., vitamin K, B vitamins), metabolizes bile acids, and influences drug metabolism. Immunologically, commensal microbes induce regulatory T cells, secrete antimicrobial peptides, and compete with pathogens for nutrients and adhesion sites, a phenomenon known as colonization resistance.

2.3 Dysbiosis and Disease

Dysbiosis refers to alterations in the composition, diversity, or function of the microbiome associated with disease. It can be characterized by loss of beneficial microbes, overgrowth of potential pathogens, or reduced diversity. In recurrent Clostridioides difficile infection, antibiotic treatment depletes the native microbiota, allowing C. difficile spores to germinate and produce toxins. In inflammatory bowel disease, reduced diversity and expansion of pro-inflammatory bacteria have been observed. Dysbiosis is also implicated in obesity, type 2 diabetes, nonalcoholic fatty liver disease, and even colorectal cancer. However, causality is often difficult to establish, and dysbiosis may be a consequence rather than a cause of disease.

3 FROM FECAL MICROBIOTA TRANSPLANTATION TO DEFINED LIVE BIOTHERAPEUTIC PRODUCTS

3.1 Fecal Microbiota Transplantation: Proof of Concept

Fecal microbiota transplantation involves the infusion of processed stool from a healthy donor into the gastrointestinal tract of a patient. It has become an established therapy for recurrent Clostridioides difficile infection, with cure rates exceeding 80–90% in multiple trials. The first randomized controlled trial demonstrating superiority over vancomycin was published in 2013. Fecal microbiota transplantation is thought to restore colonization resistance through reintroduction of a diverse microbial community.

Despite its efficacy, fecal microbiota transplantation has several limitations. Stool is a complex, undefined biological material with potential for transmission of pathogens, including multidrug-resistant organisms. Donor screening is intensive, and the product cannot be standardized across batches. In 2019, cases of invasive infections caused by extended-spectrum beta-lactamase-producing Escherichia coli transmitted via fecal microbiota transplantation prompted increased regulatory scrutiny. These concerns have driven interest in defined live biotherapeutic products, which contain characterized strains or consortia with known composition and safety profiles.

3.2 Definition and Regulatory Distinction

Live biotherapeutic products are distinct from probiotics and fecal microbiota transplantation. In the United States, the FDA regulates live biotherapeutic products as biological drugs, requiring an Investigational New Drug application and approval through a Biologics License Application. In the European Union, live biotherapeutic products are considered medicinal products and fall under the oversight of the European Medicines Agency. Key regulatory guidance includes the FDA's "Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information" and the European Pharmacopoeia's monograph on live biotherapeutic products. These documents emphasize strain identification, purity, potency, stability, and safety.

4 CLINICAL APPLICATIONS OF LIVE BIOTHERAPEUTIC PRODUCTS

4.1 Recurrent Clostridioides difficile Infection

The most advanced indication for live biotherapeutic products is prevention of recurrent C. difficile infection. Several products have shown efficacy in phase 3 trials.

SER-109: An oral microbiome therapeutic composed of purified Firmicutes spores. In the ECOSPOR III trial, SER-109 significantly reduced the proportion of patients with recurrent C. difficile infection compared with placebo (12% vs 40%) at 8 weeks. The product was well tolerated. SER-109 received FDA approval in 2023, becoming the first orally administered live biotherapeutic product for recurrent C. difficile infection.

RBX2660 (Rebyota): A rectally administered microbiota suspension derived from human stool. The PUNCH CD3 trial demonstrated that RBX2660 reduced recurrence compared with placebo (29.4% vs 42.5%) at 8 weeks. RBX2660 received FDA approval in 2022, the first live biotherapeutic product for this indication.

CP101: An orally delivered full-spectrum microbiota product. Phase 2 results showed a statistically significant reduction in recurrence compared with placebo. Further development is ongoing.

These products differ in composition, route of administration, and spectrum, but collectively validate the concept that defined microbial communities can restore colonization resistance.

4.2 Inflammatory Bowel Disease

Ulcerative colitis and Crohn's disease are associated with gut dysbiosis, but live biotherapeutic products have shown mixed results. A phase 2 trial of a defined bacterial consortium, SER-287, in mild-to-moderate ulcerative colitis demonstrated a signal of efficacy with a higher rate of clinical remission compared with placebo, but subsequent studies did not meet primary endpoints consistently. Fecal microbiota transplantation has also been studied in ulcerative colitis with moderate success, but durability and standardization remain issues. The complexity of inflammatory bowel disease and the heterogeneity of patient microbiomes complicate therapeutic development.

4.3 Other Gastrointestinal Disorders

Live biotherapeutic products are being investigated for irritable bowel syndrome, hepatic encephalopathy, and necrotizing enterocolitis in preterm infants. A phase 2 trial of the probiotic strain Lactobacillus reuteri for infant colic showed some benefit, though evidence is limited. In hepatic encephalopathy, microbiome modulation with fecal microbiota transplantation or defined consortia has been explored, but large trials are lacking.

4.4 Oncology and Immunotherapy

The gut microbiome influences responses to immune checkpoint inhibitors in cancer. Preclinical and observational studies have shown that certain bacterial species, such as Akkermansia muciniphila and Bifidobacterium, are associated with improved responses to anti-PD-1 therapy. Live biotherapeutic products containing these strains are being tested as adjuncts to immunotherapy. Early-phase trials have demonstrated feasibility and potential enhancement of anti-tumor immunity. For example, a phase 1 trial combining a defined bacterial consortium with nivolumab in patients with advanced solid tumors reported preliminary signals of efficacy. However, larger randomized trials are needed.

4.5 Metabolic and Other Indications

Preclinical data suggest that specific microbes can improve insulin sensitivity, reduce hepatic steatosis, or modulate cholesterol metabolism. Clinical evidence for live biotherapeutic products in metabolic diseases is still nascent. A phase 2 trial of a butyrate-producing bacterial strain in type 2 diabetes showed improvements in glycemic control in a subset

of patients, but results were not consistent. Similarly, trials in atopic dermatitis and asthma have produced variable outcomes. The field is shifting toward identifying patient subsets with defined dysbiosis signatures that may respond to targeted microbial restoration.

5 REGULATORY, MANUFACTURING, AND SAFETY CONSIDERATIONS

5.1 Regulatory Framework

In the US, live biotherapeutic products are regulated as biological products under section 351 of the Public Health Service Act. Sponsors must provide comprehensive chemistry, manufacturing, and control information, including strain identity, genetic stability, purity, and absence of antibiotic resistance genes of concern. Early-phase trials require rigorous donor screening and product characterization. In the EU, the European Pharmacopoeia monograph "Live Biotherapeutic Products for Human Use" outlines quality requirements, including identity, viability, and microbial purity. The regulatory landscape continues to evolve, with ongoing efforts to harmonize standards internationally.

5.2 Manufacturing Challenges

Unlike small molecules, live biotherapeutic products are living organisms that require specialized manufacturing processes. Strain banks must be characterized and maintained to ensure genetic stability. Fermentation, downstream processing, and formulation must preserve viability and potency. Lyophilization is often used to improve shelf life, but viability after reconstitution must be demonstrated. Batch-to-batch consistency is a challenge, particularly for consortia containing multiple strains. Analytical methods for potency and purity are less standardized than for conventional biologics.

5.3 Safety

Live biotherapeutic products are generally considered safe in immunocompetent populations, but concerns remain for immunocompromised patients. Bacteremia and fungemia have been reported with probiotic use in severely ill or immunosuppressed individuals. The FDA requires exclusion of microorganisms with transferable antibiotic resistance genes and virulence factors. Long-term effects on the resident microbiota and the potential for horizontal gene transfer require ongoing surveillance. Post-marketing studies and registries are needed to monitor rare adverse events.

6 FUTURE PERSPECTIVES

The field of live biotherapeutic products is poised for significant growth. Advances in metagenomics, culturomics, and synthetic biology are enabling the design of defined consortia with predictable functions. Engineered microbes that express therapeutic proteins or sense disease biomarkers are being developed. For example, bacteria engineered to produce anti-inflammatory cytokines or enzymes that degrade toxins are in preclinical development. Microbiome-based diagnostics may enable patient stratification, identifying individuals most likely to benefit from a specific live biotherapeutic product. Combination approaches with diet, prebiotics, or drugs may enhance engraftment and efficacy. Regulatory frameworks will need to adapt to the unique challenges of engineered live biotherapeutics, including containment and biocontainment. Large, well-controlled trials with standardized products and predefined endpoints will be essential to move beyond anecdotal evidence.

7 CONCLUSION

The human microbiome is a critical determinant of health and disease, and its therapeutic modulation through live biotherapeutic products represents a paradigm shift in medicine. The transition from fecal microbiota transplantation to defined, standardized live biotherapeutic products has been catalyzed by regulatory advances and successful clinical trials in recurrent Clostridioides difficile infection. While this indication has provided proof of concept, expansion to inflammatory bowel disease, oncology, and metabolic disorders will require a deeper understanding of microbial mechanisms and patient-specific dysbiosis. Manufacturing, safety, and regulatory challenges remain, but ongoing innovation in strain selection, engineering, and trial design is likely to unlock the therapeutic potential of the microbiome.

REFERENCES

[1] Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–2379.

[2] Gilbert JA, Blaser MJ, Caporaso JG, et al. Current understanding of the human microbiome. Nat Med. 2018;24(4):392–400.

[3] van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415.

[4] US Food and Drug Administration. Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. Guidance for industry. Silver Spring, MD: FDA; 2016.

[5] European Pharmacopoeia. Live biotherapeutic products for human use. Ph. Eur. Monograph 3053. Strasbourg: European Directorate for the Quality of Medicines; 2019.

[6] Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220–229.

[7] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase 3, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527–1538.

[8] DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–2050.

[9] Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729.

[10] Sorbara MT, Pamer EG. Microbiome-based therapeutics. Nat Rev Microbiol. 2022;20(6):365–380.

[11] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228.

[12] Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–109.e6.

[13] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97.

[14] Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28(4):704–712.

[15] Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716–1725.

[16] O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2:17057.

[17] Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616.

[18] Ducarmon QR, Zwittink RD, Hornung BVH, et al. Gut microbiota and colonization resistance against bacterial enteric infection. Microbiol Mol Biol Rev. 2019;83(3):e00007-19.

[19] Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021;18(1):67–80.

[20] Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol. 2018;34(1):3–10.